KALV - カ―ビラン・セラピュ―ティクス (KalVista Pharmaceuticals Inc.) カ―ビラン・セラピュ―ティクス

 KALVのチャート


 KALVの企業情報

symbol KALV
会社名 KalVista Pharmaceuticals Inc (カ―ビラン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 KalVista Pharmaceuticals Inc. formerly Carbylan Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery development and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate KVD818 is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.   カ―ビラン・セラピュ―ティクスは、米国のバイオ医薬品会社。満たされていない医療ニ―ズに対応する併用療法の開発と商業化に焦点を当て事業を展開する。変形性膝関節症に関連する痛みを治療するための医薬品として、関節内注射用製品候補であるハイドロス-TAを提供する。本社所在地はカリフォルニア州。   KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
本社所在地 55 Cambrigge Parkway Suite 901E Cambridge MA 02142 USA
代表者氏名 Richard Aldrich リチャード・アルドリッチ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 857-999-0075
設立年月日 38047
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 33人
url www.kalvista.com
nasdaq_url https://www.nasdaq.com/symbol/kalv
adr_tso
EBITDA EBITDA(百万ドル) -20.06300
終値(lastsale) 17.465
時価総額(marketcap) 300043233.455
時価総額 時価総額(百万ドル) 339.64240
売上高 売上高(百万ドル) 12.01600
企業価値(EV) 企業価値(EV)(百万ドル) 291.78640
当期純利益 当期純利益(百万ドル) -15.90700
決算概要 決算概要 BRIEF: For the three months ended 31 July 2018 Kalvista Pharmaceuticals Inc revenues increased from $96K to $3.7M. Net loss increased 2% to $5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $3.5M to $8.4M (expense) General and administrative increase of 14% to $2.4M (expense).

 KALVのテクニカル分析


 KALVのニュース

   KalVista Pharmaceuticals Reports First Fiscal Quarter Results  2020/09/14 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update and released financial results for the first fiscal quarter ended July 31, 2020. “We are pleased that our KVD900 Phase 2 trial has met its enrollment target and data is expected before the end of this year. We believe K
   KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference  2020/09/11 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 8:40 am ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio ar
   KalVista Pharmaceuticals to Present at BTIG Virtual Biotechnology Conference  2020/08/03 11:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be avail
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results | | IT Business Net  2020/07/01 12:02:15 IT Business Net
– KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2
   KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results  2020/07/01 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided an operational update and released financial results for the fiscal year ended April 30, 2020. “We have two oral candidates in clinical trials that have the potential to provide HAE patients with a complete set of options to treat their disea
   KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference  2020/04/09 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Virtual Healthcare Conference on Wednesday, April 15, 2020, at 11:20 a.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com. An audio archive will be av
   KalVista Pharmaceuticals Provides Operational and Financial Update  2020/04/07 11:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced potential impact of coronavirus disease 2019 (COVID-19) on its ongoing operations and provided revised financial guidance that activities are funded into at least early 2022. “Patient safety remains our top priority,” said Andrew Crockett, C
   KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs  2020/02/10 21:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the option agreement between KalVista and Merck related to intravitreal diabetic macular edema (DME) candidate KVD001 and future oral DME molecules has expired. “We appreciate Merck’s willingness to work with us on the advancement of p
   The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx  2020/02/04 12:35:00 Zacks Investment Research
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
   KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug  2019/12/09 14:15:15 Benzinga Feeds
Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) are seen moving to the downside Monday. … Full story available on Benzinga.com
   KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs  2020/02/10 21:30:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that the option agreement between KalVista and Merck related to intravitreal diabetic macular edema (DME) candidate KVD001 and future oral DME molecules has expired. “We appreciate Merck’s willingness to work with us on the advancement of p
   The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx  2020/02/04 12:35:00 Zacks Investment Research
The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx
   KalVista Shares Sink On Failed Mid-Stage Study Of Diabetic Macular Edema Drug  2019/12/09 14:15:15 Benzinga Feeds
Shares of thinly-traded micro-cap biotech Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) are seen moving to the downside Monday. … Full story available on Benzinga.com
   KalVista Pharmaceuticals Reports Phase 2 Clinical Trial Results in Patients with Diabetic Macular Edema  2019/12/09 12:00:00 Business Wire
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema (DME). The KVD001 Phase 2 clinical trial study was designed to evaluate patients who were poor responders to previous treatment with
   KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?  2019/12/06 12:42:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

 関連キーワード  (医薬品 米国株 カ―ビラン・セラピュ―ティクス KALV KalVista Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)